company background image
AMTI

Applied Molecular Transport NasdaqGS:AMTI Stock Report

Last Price

US$1.12

Market Cap

US$43.6m

7D

-10.4%

1Y

-95.9%

Updated

23 Sep, 2022

Data

Company Financials +
AMTI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AMTI Stock Overview

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.

Applied Molecular Transport Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Applied Molecular Transport
Historical stock prices
Current Share PriceUS$1.12
52 Week HighUS$28.86
52 Week LowUS$1.02
Beta1.3
1 Month Change-32.12%
3 Month Change-69.65%
1 Year Change-95.91%
3 Year Changen/a
5 Year Changen/a
Change since IPO-93.77%

Recent News & Updates

Aug 04

Applied Molecular Transport GAAP EPS of -$0.93

Applied Molecular Transport press release (NASDAQ:AMTI): Q2 GAAP EPS of -$0.93. Cash, cash equivalents and investments. As of June 30, 2022, cash and cash equivalents were $95.8 million.

Jul 27
Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky

Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Jul 05

Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data

Shares of Applied Molecular Transport (NASDAQ:AMTI) are up ~4% in after-hours trading after the company said it will release top-line results from a phase 2 trial of AMT-101 for ulcerative colitis before Wednesday's opening bell. The trial enrolled biologic-naive patients with moderate-to-severe disease. AMT-101 was given with a TNFα inhibitor. AMT-101 is a GI-selective, oral recombinant biologic fusion protein of human interleukin 10 (hIL-10). In May, Applied Molecular implemented a cost and workforce cutting plan.

Shareholder Returns

AMTIUS BiotechsUS Market
7D-10.4%-5.0%-5.2%
1Y-95.9%-30.0%-23.1%

Return vs Industry: AMTI underperformed the US Biotechs industry which returned -30.9% over the past year.

Return vs Market: AMTI underperformed the US Market which returned -21.6% over the past year.

Price Volatility

Is AMTI's price volatile compared to industry and market?
AMTI volatility
AMTI Average Weekly Movement12.0%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.8%

Stable Share Price: AMTI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: AMTI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2010125Tahir Mahmoodhttps://www.appliedmt.com

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company’s lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects.

Applied Molecular Transport Inc. Fundamentals Summary

How do Applied Molecular Transport's earnings and revenue compare to its market cap?
AMTI fundamental statistics
Market CapUS$43.57m
Earnings (TTM)-US$134.71m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMTI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$32.83m
Gross Profit-US$32.83m
Other ExpensesUS$101.88m
Earnings-US$134.71m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.46
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did AMTI perform over the long term?

See historical performance and comparison